Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Role of CRMP2 and Pin1 in the pathogenesis of Alzheimer’s disease

AD PATHOGENESIS

Collapsin response mediator protein 2 (CRMP2) is essential for neural development and function. It promotes axon growth but upon its phosphorylation it mediates axon retraction. Deregulation of CRMP2 has been implicated in Alzheimer’s disease (AD) where CRMP2 was detected to form hyperphosphorylated aggregates within neurofibrillary tangles. The...

Funding Programme
EU-FP7
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Stabilizing pharmaco-active Membrane proteins with Zwitterionic polymers and leveraging Surface Plasmon Resonance as an Analytical platform

ZwitterMPs

Membrane proteins, particularly G-protein-coupled receptors (GPCRs), represent 25-30% of current drug targets. Among them, metabotropic glutamate receptor (mGluR), a Class C and group 1 type GPCR, is emerging as an attractive therapeutic target for various neurological and psychiatric disorders such as Alzheimer’s disease, Parkinson's disease...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 207 758
European Countries Involved

STED-enabled super-resolution multimode-fibre based holographic endoscopy for deep-tissue observations of neuronal connectivity

STEDGate

Neurological disorders have emerged as a significant global societal burden, exemplified by afflictions like Alzheimer's and Parkinson's, impacting over one billion individuals globally and surpassing the combined economic burden of cancer and diabetes. This has spurred a concerted global effort, with increased support for neuroscience research...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Support, Monitoring and Reminder Technology for Mild Dementia

SMART4MD

As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 3 834 555
European Countries Involved

Targeted small-molecule Stabilisation of Protein-Protein Interactions

TASPPI

The goal of the TASPPI European Training Network (ETN) is the establishment of a highly interdisciplinary research and educational training platform for early stage scientists in the Chemical Life Sciences to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 3 342 323
European Countries Involved

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

TClock4AD

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 3 811 636

THERAPEUTIC AND PREVENTIVE IMPACT OF NUTRITIONAL LIPIDS ON NEURONAL AND COGNITIVE PERFORMANCE IN AGING, ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA

LIPIDIDIET

Major objective: It is our aim to develop a lipid based diet that is able to delay or prevent onset of Alzheimer’s disease and related diseases and has a stabilizing effect on cognitive performance in aging. Multiple lines of evidence suggest that there is a large overlap between risk factor of these three diseases. Importantly, there is equally...

Funding Programme
EU-FP7
Start Date
End Date
Total Funding
€ 7 995 577
European Countries Involved

Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS

TREM2MEDS

TREM2MEDS emerges from the ERC PoC 2022 project TREM2ENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimers Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 2 499 721
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).